MetLife previews 2025 results and $2.85B share repurchases

MetLife, Inc. is providing an early look at certain 2025 results and its capital deployment plans.

Rhea-AI Filing Summary

MetLife, Inc. is providing an early look at certain 2025 results and its capital deployment plans. For the quarter ending December 31, 2025, it estimates variable investment income of approximately $385 million to $435 million (pre-tax), compared with a quarterly target of $425 million (pre-tax) based on full-year 2025 guidance of about $1.7 billion (pre-tax). For full year 2025, MetLife anticipates a 7.7% return on its private equity portfolio and plans to use an assumed 9% annual return in its 2026 outlook, contributing to an estimated $1.6 billion (pre-tax) of variable investment income in 2026.

The company expects to deploy about $4 billion of capital in 2025 to support organic growth and approximately $1 billion for merger and acquisition activity, including funding for the expected closing of its previously announced PineBridge Investments acquisition. Total common stock repurchases for 2025 are expected to be about $2.85 billion, including roughly $430 million in the fourth quarter, with a similar repurchase level anticipated in 2026. All figures are preliminary, unaudited and subject to change as year-end closing procedures are completed.

Insights

Insurance sector equity analyst

MetLife outlines preliminary variable investment income and sizable 2025–2026 capital deployment.

MetLife is giving early indications of how its investment portfolio and capital strategy are shaping results. For Q4 2025, it estimates variable investment income of $385 million to $435 million (pre-tax) versus a stated quarterly target of $425 million, tied to full-year 2025 guidance of about $1.7 billion. It also reports an anticipated full-year 2025 private equity portfolio return of 7.7%, and is using a 9% assumed annual return for 2026, implying about $1.6 billion of variable investment income next year.

On capital management, the company plans to deploy about $4 billion in 2025 to support organic growth and approximately $1 billion for merger and acquisition activity, including funding for the expected closing of the PineBridge Investments acquisition. It expects total common stock repurchases of roughly $2.85 billion in 2025, with around $430 million in Q4, and anticipates a similar repurchase level in 2026. These figures provide clarity on how much cash is being directed to growth, deals, and share repurchases, while the company notes that variable investment income asset balances are expected to decrease over the near term of one to three years.

The company emphasizes that all 2025 figures are preliminary, unaudited and based on information available as of December 22, 2025, and that actual results could differ materially once financial closing procedures are complete. It also highlights that its outlook depends on assumptions about economic and business conditions and may be revised as it gains more information on regulatory changes, market conditions and their impact on its operations and investment portfolio.

8-K Event Classification

Item 7.01 — Regulation FD Disclosure

1 item

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

FAQ

What preliminary variable investment income does MetLife (MET) expect for Q4 2025?

MetLife estimates its variable investment income for the quarter ending December 31, 2025 will be approximately $385 million to $435 million (pre-tax), compared with a quarterly target of $425 million (pre-tax) based on full-year 2025 guidance of about $1.7 billion (pre-tax).

What return does MetLife (MET) anticipate on its private equity portfolio for 2025?

For full year 2025, MetLife anticipates a 7.7% return on its private equity investment portfolio, based on preliminary results received to date.

How much variable investment income does MetLife (MET) project for 2026?

For its 2026 outlook, MetLife plans to use an assumed 9% annual return on its private equity portfolio, which it states would contribute to about $1.6 billion (pre-tax) of total estimated variable investment income for full year 2026.

What are MetLife’s (MET) capital deployment plans for 2025?

MetLife’s first priority is to support organic growth, with an estimated $4 billion deployed in 2025, plus approximately $1 billion in 2025 to support merger and acquisition activity, including funding for the expected closing of its previously announced acquisition of PineBridge Investments.

How much common stock does MetLife (MET) expect to repurchase in 2025 and 2026?

For full year 2025, MetLife expects total common stock repurchases of about $2.85 billion, including roughly $430 million in the quarter ending December 31, 2025, and it anticipates a similar level of common stock repurchases in 2026.

What does MetLife (MET) say about future variable investment income asset balances?

MetLife states that it anticipates its variable investment income asset balances will decrease over the near term, which it describes as one to three years.

Are MetLife’s (MET) preliminary 2025 figures final and audited?

No. MetLife explains that the preliminary financial information for the quarter and full year ending December 31, 2025 is estimated and unaudited, prepared based on information available to management, and that actual results could be materially different once financial closing procedures are completed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/22/2025 - 06:18 AM Learn about SEC filing dates

0001099219false00010992192025-12-222025-12-220001099219us-gaap:CommonStockMember2025-12-222025-12-220001099219us-gaap:SeriesAPreferredStockMember2025-12-222025-12-220001099219us-gaap:SeriesEPreferredStockMember2025-12-222025-12-220001099219us-gaap:SeriesFPreferredStockMember2025-12-222025-12-22

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549  

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): December 22, 2025

METLIFE, INC.

(Exact Name of Registrant as Specified in Its Charter)

Delaware

(State or Other Jurisdiction of Incorporation)

1-15787

13-4075851

(Commission File Number)

(IRS Employer Identification No.)

200 Park Avenue,

New York,

NY

10166-0188

(Address of Principal Executive Offices)

(Zip Code)

(212) 578-9500

(Registrant’s Telephone Number, Including Area Code)

N/A

(Former Name or Former Address, if Changed Since Last Report) 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock, par value $0.01			MET			New York Stock Exchange
Floating Rate Non-Cumulative Preferred Stock, Series A, par value $0.01			MET PRA			New York Stock Exchange
Depositary Shares, each representing a 1/1,000th interest in a share of 5.625% Non-Cumulative Preferred Stock, Series E			MET PRE			New York Stock Exchange
Depositary Shares, each representing a 1/1,000th interest in a share of 4.75% Non-Cumulative Preferred Stock, Series F			MET PRF			New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company    ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ☐

Item 7.01 Regulation FD Disclosure.

MetLife, Inc. (the "Company") is furnishing this Current Report on Form 8-K to disclose certain preliminary results and outlook information prior to the availability of the Company’s quarterly earnings release, quarterly financial supplement and outlook materials for the quarter and full year ending December 31, 2025, scheduled for release on February 4, 2026.

Variable Investment Income

Based on preliminary results received to date, for the quarter ending December 31, 2025, the Company estimates that its variable investment income will be approximately $385 million to $435 million (pre-tax), relative to its quarterly target of $425 million (pre-tax) (based on full-year 2025 guidance of approximately $1.7 billion (pre-tax)). Variable investment income includes private equity, real estate and other funds and prepayment fees.

Based on preliminary results received to date, for full year 2025, the Company anticipates a return on its private equity investment portfolio of approximately 7.7%. Additionally, for its outlook in 2026, the Company will incorporate an assumed 9% annual return on its private equity portfolio, which would contribute to $1.6 billion (pre-tax) of total estimated variable investment income for full year 2026. Further, the Company anticipates variable investment income asset balances will decrease over the near term (one to three years).

Capital Management

The Company’s first priority for capital deployment is to support organic growth opportunities, with an estimated total of $4 billion deployed in 2025, and an additional approximately $1 billion in 2025 to support merger and acquisition activity, including funding for the expected closing of the Company’s previously announced acquisition of PineBridge Investments. For the full year 2025, the Company expects its total common stock repurchases will be approximately $2.85 billion, including approximately $430 million in the quarter ending December 31, 2025. The Company anticipates a similar level of common stock repurchases in 2026.

Forward-Looking Statements and Other Information

The preliminary financial information presented above for the quarter and full year ending December 31, 2025, is estimated and unaudited and has been prepared in good faith on a basis consistent with prior periods based on information available to management as of the date hereof; however, we have not completed our financial closing procedures for the quarter ending December 31, 2025, and our actual results could be materially different from these preliminary financial results. As a result, prospective investors should exercise caution in relying on this information and should not draw any inferences from this information regarding financial or operating data not provided. These preliminary financial results should not be viewed as a substitute for full financial statements prepared in accordance with U.S. GAAP. In addition, these preliminary financial results are not necessarily indicative of the results to be achieved in any future period. The Company’s outlook relies on the accuracy of its assumptions about future economic and business conditions, which can be affected by known and unknown risks, uncertainties and other factors. The Company continually reviews its assumptions, implements mitigation plans, and takes precautions. The Company may revise its outlook as it obtains more information regarding economic conditions, regulatory changes, and other events, and the impact of these events on its business operations, investment portfolio, derivatives, financial results and financial condition.

The forward-looking statements in this disclosure, which use terms such as “anticipates,” “assumptions,” “estimates,” “expects,” “guidance,” “outlook,” “preliminary,” “target” and “will,” are based on assumptions and expectations that involve risks and uncertainties, including the “Risk Factors” MetLife, Inc. describes in its U.S. Securities and Exchange Commission filings. MetLife, Inc.’s results could differ materially from those it expresses or implies in forward-looking statements. MetLife, Inc. does not undertake any obligation to publicly correct or update any forward-looking statement if MetLife, Inc. later becomes aware that such statement is not likely to be achieved.

As provided in General Instruction B.2 of Form 8-K, the information provided pursuant to this Item 7.01 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

METLIFE, INC.

By:

/s/ Adrienne O’Neill

Name:

Adrienne O’Neill

Title:

Executive Vice President and Chief Accounting Officer

Date: December 22, 2025

3